Daraxonrasib (Rasonque) is now FDA approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or for those who are not candidates for multiagent regimens. The approval was granted 6.5 months early and introduces a first-in-class daily oral RAS inhibitor into pancreatic cancer care.
Key Clinical Data: RASolute‑302
The pivotal phase 3 trial enrolled previously treated patients with metastatic pancreatic adenocarcinoma. Results demonstrated clinically meaningful and statistically robust improvements:
- Overall survival: 13.2 months with daraxonrasib vs 6.7 months with chemotherapy
- Progression‑free survival: Approximately doubled
- Quality of life: Improved functional and symptom scores
- Safety: Manageable toxicity profile; lower rates of severe cytopenias compared with chemotherapy
These outcomes represent the most significant survival improvement seen to date in a randomized pancreatic cancer study.
Approved Patient Population
Daraxonrasib is indicated for adults with metastatic pancreatic adenocarcinoma who:
- Have received ≥1 prior systemic therapy, or
- Are not candidates for multiagent systemic therapy
This aligns with real‑world practice, where many patients present with poor performance status or rapidly progressive disease.
Clinical Implications for Oncologists
Daraxonrasib’s approval introduces a new standard for second‑line and later‑line care:
- Chemotherapy‑free oral option for frail or heavily pretreated patients
- Potential for earlier‑line integration pending ongoing studies
- Opens the door for RAS‑targeted combinations (eg, with immunotherapy or metabolic inhibitors)
- May shift molecular testing practices toward more routine RAS profiling
